2024 Laboratory Reimbursement Trends and What to Expect in 2025
Revenue cycle management experts weigh in on the biggest developments of 2024 and how labs can best prepare for 2025 and beyond
Keep up to date on the latest legal, compliance, and business developments affecting the lab industry, while offering analysis and insight to ensure your lab’s success.
Revenue cycle management experts weigh in on the biggest developments of 2024 and how labs can best prepare for 2025 and beyond
Recent case shows why failing to disclose to individuals the lab test list prices they may need to pay doesn’t count as consumer fraud.
In terms of Medicare coverage, 2023 is shaping up to be a fruitful year—here are five of the most significant approvals so far.
Increasing medical and consumer debt is likely to get worse, meaning billing and collections may get even tougher for labs.
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.
The wave of layoffs, which began last year with the declines in COVID-19 testing sales, has gathered momentum in 2023.
The bill is designed to provide Medicare patients faster access to innovative technology approved by the FDA.
April was among the busiest months, in recent memory, in terms of both deal volume and significance in the diagnostics industry.
A recent court case sheds some light on if denying employment can count as illegal remuneration under the Anti-Kickback Statute.
Two companies settle kickback and FCA-related claims, a qui tam case is tossed, and a lab tech loses a workplace harassment case.
In an analysis of enforcement actions from the end of 2022 to early spring 2023, cases involving urine drug testing were the most prevalent.